Page 17 - MemoriaEHD-Eng
P. 17
www.ciberehd.org
• Most of the groups have participated in multicentre Clinical Trials with new
combinations of HCV direct acting antivirals.
• Clinical trials using new antiviral strategies (lethal mutagenesis) and new
inhibitors (quercetine, etc) have been proposed and will be developed in
next years.
As a summary, the activity developed during 2013 in the Area 2 of Ciberehd has
been successful and has increase the competitive research capability of our net-
work. Juan I Esteban.
13
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C
17
